Last reviewed · How we verify
Advanced Breast Cancer Progression Post-Antiestrogen Therapy — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aromasin | exemestane | Pfizer | Aromatase Inhibitor [EPC] | Aromatase | 1999-01-01 | |
| Aromasin | Aromasin | Pfizer | Androgen receptor, Aromatase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Advanced Breast Cancer Progression Post-Antiestrogen Therapy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Advanced Breast Cancer Progression Post-Antiestrogen Therapy:
- Advanced Breast Cancer Progression Post-Antiestrogen Therapy treatment updates — RSS
- Advanced Breast Cancer Progression Post-Antiestrogen Therapy treatment updates — Atom
- Advanced Breast Cancer Progression Post-Antiestrogen Therapy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Advanced Breast Cancer Progression Post-Antiestrogen Therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-breast-cancer-progression-post-antiestrogen-therapy. Accessed 2026-06-10.
Related
- Advanced Breast Cancer Progression Post-Antiestrogen Therapy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing